Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.

about

Current use of factor concentrates in pediatric cardiac anesthesia.Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies.

P2860

Q36341729-6F837DFA-0EB8-4259-A73A-A9D4C10DDAD9 Q52725146-701E90ED-FDFB-4067-95CE-C58B38C51F22

P2860

Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.

Item

http://www.wikidata.org/entity/Q36956166

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Correcting thrombin generation ...... use of cardiopulmonary bypass.

@en

type

Item

label

Correcting thrombin generation ...... use of cardiopulmonary bypass.

@en

prefLabel

Correcting thrombin generation ...... use of cardiopulmonary bypass.

@en

P1476

Correcting thrombin generation ...... use of cardiopulmonary bypass.

@en

P2093

Charles L Percy

http://www.w3.org/2001/XMLSchema#string

Dheeraj Mehta

http://www.w3.org/2001/XMLSchema#string

Friedrich Scheiflinger

http://www.w3.org/2001/XMLSchema#string

Judith E Hall

http://www.w3.org/2001/XMLSchema#string

Michael Dockal

http://www.w3.org/2001/XMLSchema#string

Peter W Collins

http://www.w3.org/2001/XMLSchema#string

Rhidian M Jones

http://www.w3.org/2001/XMLSchema#string

Rudolf Hartmann

http://www.w3.org/2001/XMLSchema#string

Subramaniam Balachandran

http://www.w3.org/2001/XMLSchema#string

P2860

Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model

Small Peptides Blocking Inhibition of Factor Xa and Tissue Factor-Factor VIIa by Tissue Factor Pathway Inhibitor (TFPI)

Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay

The hemostatic profile of recombinant activated factor VII. Can low concentrations stop bleeding in off-label indications?

Thrombin generation capacity of prothrombin complex concentrate in an in vitro dilutional model.

Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery

Use of blood products and risk of stroke after coronary artery bypass surgery.

Use of recombinant activated factor VII for controlling refractory postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass.

Salvage use of activated recombinant factor VII in the management of refractory bleeding following cardiac surgery.

P304

357-367

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MBC.0000000000000243

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Valerie O'Donnell

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25928274

http://www.w3.org/2001/XMLSchema#string

P921

cardiac surgery

P932

4888920

http://www.w3.org/2001/XMLSchema#string

Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.

about

P2860

P2860

Correcting thrombin generation ex vivo using different haemostatic agents following cardiac surgery requiring the use of cardiopulmonary bypass.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932